Compare Lockheed Martin Corporation (LMT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Summit Therapeutics Inc — how do they compare? Lockheed Martin Corporation trades at $606.32 (market cap $137.96B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: Lockheed Martin Corporation is far larger — about 11.4× Summit Therapeutics Inc's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LMT | SMMT | |
|---|---|---|
Market Cap | $137.96B | $12.06B |
Sector | Industrials | Health |
52-Week High | $676.70 | $26.98 |
52-Week Low | $431.56 | $12.55 |
Enterprise Value | $154.71B | $11.39B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $601.99, down 0.19% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a record $230.4 billion backlog (Seeking Alpha, 2026-08-04), revenue growth to $75.05 billion in 2025, and a net income margin of 8.16%. Recent news highlights major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, 2026-08-11), supporting long-term growth.
The outlook for LMT is positive, driven by expanding defense budgets and execution on its backlog, though risks include earnings misses and debt levels. Analysts project a consensus price target of $608, with 57% recommending buy. The stock's valuation metrics, such as a P/E of 22.04, appear reasonable given growth prospects, but investors should monitor contract execution and macroeconomic pressures.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
